![Page 1: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/1.jpg)
RESUMEN DE ESTUDIO 2016
CRITERIOS DE INCLUSION –EXCLUSION PARA TROMBOLISIS INTRAVENOSA
MAURICIO USME
URGENTOLO UNIVERSIDAD DE ANTIOQUIA
1
![Page 2: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/2.jpg)
2
![Page 3: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/3.jpg)
3
![Page 4: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/4.jpg)
SOLO
22-31% PTES LLEGAN ER
< 3HRS SINTOMAS ACV
Elegibles aun en ventana 30% de los pacientes
4
![Page 5: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/5.jpg)
5
![Page 6: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/6.jpg)
6
![Page 7: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/7.jpg)
Caída en 4 puntos del nihss o muerte o PH2 en 36 horas pos trombolisis
7
![Page 8: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/8.jpg)
8
![Page 9: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/9.jpg)
9
![Page 10: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/10.jpg)
10
![Page 11: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/11.jpg)
11
![Page 12: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/12.jpg)
• Los déficits menores de 5 puntos y mayores a 25 NO SON CONTRAINDICACIÓN absoluta pata trombolisis
1. Déficits mínimo <5 puntos 2. Stroke leve <20 puntos 3. Déficits neurológico severo >22 < 25 4. Stroke severo > 25 puntos
12
![Page 13: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/13.jpg)
13
![Page 14: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/14.jpg)
14
![Page 15: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/15.jpg)
15
![Page 16: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/16.jpg)
16
![Page 17: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/17.jpg)
17
![Page 18: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/18.jpg)
18
![Page 19: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/19.jpg)
19
![Page 20: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/20.jpg)
20
![Page 21: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/21.jpg)
21
![Page 22: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/22.jpg)
22
![Page 23: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/23.jpg)
23
![Page 24: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/24.jpg)
24
![Page 25: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/25.jpg)
• Mortalidad de ACV en pacientes diálisis dependientes 10% vs ACV en pacientes sin diálisis SIN tto con trombolitico
• La sola enfermedad renal de base alta mortalidad independiente de la trombolisis PERO se debe trombolizar si tp tpt inr normal
25
![Page 26: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/26.jpg)
26
![Page 27: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/27.jpg)
27
![Page 28: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/28.jpg)
• Se debe dar en paciente si cumplen criterios de inclusión.
28
![Page 29: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/29.jpg)
29
![Page 30: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/30.jpg)
30
![Page 31: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/31.jpg)
31
![Page 32: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/32.jpg)
32
![Page 33: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/33.jpg)
33
![Page 34: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/34.jpg)
34
![Page 35: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/35.jpg)
35
![Page 36: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/36.jpg)
36
![Page 37: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/37.jpg)
37
![Page 38: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/38.jpg)
38
![Page 39: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/39.jpg)
39
![Page 40: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/40.jpg)
40
![Page 41: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/41.jpg)
41
![Page 42: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/42.jpg)
42
![Page 43: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/43.jpg)
43
![Page 44: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/44.jpg)
44
![Page 45: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/45.jpg)
45
![Page 46: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/46.jpg)
46
![Page 47: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/47.jpg)
47
![Page 48: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/48.jpg)
48
![Page 49: acv isquemico 2016 AHA criterios inclusion y exclusion actualizados](https://reader031.vdocuments.site/reader031/viewer/2022020314/5884d0ed1a28ab767c8b6269/html5/thumbnails/49.jpg)
49